Mandate

Vinge advises Capio in connection with the acquisition of the Nova clinics

February 26, 2018 M&A

Vinge has advised Capio, which is listed on Nasdaq Stockholm, in connection with the acquisition of the shares in the Nova clinics.

The Nova clinics primarily conduct healthcare operations at eight clinics in the southeast of Skåne and have certain operations within occupational health service and dental service. In 2017, the Nova clinics had a turnover of approximately MSEK 245 and had approximately 45 000 listed patients. The purchase price mechanism, which is based on Enterprise Value, amounts to MSEK 88. The acquisition is conditional upon the Swedish Competition Authority’s and Region Skåne’s approval.

Vinge’s team consisted of Anders Strid, Frida Bäckegren (project manager), Gabriella Fossum (LOU), Rebecka Maltenius (commercial property law), Lina André (employment law), Camilla Andersson (company registration assistant) as well as Pär Remenlid and Nils Alvång (both competition law).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025